89bio reports positive topline results from an expansion cohort of the phase 1b/2a trial of pegozafermin (bio89-100) for the treatment of nash

San francisco, jan. 24, 2022 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced positive topline results from an open-label expansion cohort of 20 patients (cohort 7) in the phase 1b/2a proof-of-concept study evaluating pegozafermin (formerly bio89-100) for the treatment of nash.
ETNB Ratings Summary
ETNB Quant Ranking